1. Scrip
  2. >>Therapy Areas
  3. >>Anticancer

BeiGene’s Tislelizumab Delivers With OS Data In Broad Gastric Cancer Population

 
• By Jessica Merrill

The PD-L1 inhibitor partnered with Novartis improved overall survival in combination with chemotherapy in gastric cancer patients regardless of PD-L1 status.

applause
Tislelizumab improved overall survival in gastric cancer • Source: Shutterstock

BeiGene, Ltd.’s PD-L1 inhibitor tislelizumab improved overall survival in combination with chemotherapy in patients with advanced unresectable or metastatic gastric or gastroesophageal junction (G/GEJ) adenocarcinoma regardless of PD-L1 status in a Phase III clinical trial, the company reported on 20 April.

The positive data add to the growing efficacy evidence for the drug, which is approved for 10 indications in China...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Anticancer

More from Therapy Areas

Scholar Rock Shows Muscle-Building PoC In Obesity

 
• By Jessica Merrill

The company said it intends to maintain a focus on rare neuromuscular disease with apitegromab but could consider partnering in obesity.

Spyre Takes Aim At Roche And J&J In Inflammatory Diseases

 
• By Andrew McConaghie

The US firm was already looking to compete in ulcerative colitis, but now expands its ambitions by moving into rheumatoid arthritis as well.

Draig Is All Fired Up To Transform Neuropsychiatric Field

 
• By Kevin Grogan

Wales-based group launches with $140m series A.